Cyclin A immunohistochemistery in Wilms tumor

Abstract

Introduction:In human malignancies, cyclin A overexpression is related to worse prognosis. We examined the relationships between cyclin A immunohistochemistry expression and the clinicopathological features of Wilms tumor (WT), preoperative chemotherapy (PrOpChTh), overall survival (OS), and other factors. Aim of the study:We systematically reviewed the literature on the prognostic value of Cyclin A IHC in Wilms tumors. Subjects and Methods:We searched for English language studies on PubMed from 2018 to 2023 about Cyclin A immunohistochemistry in patients younger than 18 years with Wilms tumors. We found two studies about that article, a retrospective study and a non-concurrent cohort study including patients who underwent nephrectomy for WT from January 1996 to December 2015 in a tertiary referral center.Results: According to the two reviewed studies, Patients with WTs had 33.4% higher cyclin A expression.Blastemal components were much more overexpressed in stage 3 and stage 4 cancers (77.8% and 66.7%, respectively). Cyclin A was discovered to be overexpressed in 66.7% of metastasizing patients but only 33.3% of non-metastasizing patients. High recurrence rates were also connected to CSM and cyclin A immunopositivity. Risk factors such as advanced stage, UFH, extracapsular extension, tumor rupture, lymphadenopathy, and venous thrombosis were not associated with a poor prognosis. Patients who have had recurrences have a worse likelihood of survival. Conclusions: Overexpression ofCyclin A in WT may indicate a bad prognosis. More patients should be included in future studies. WT's capacity to spread metastatically was unaffected by cyclin A overexpression. More people would be required to adequately investigate the link between cyclin A overexpression and poor outcomes in WT individuals.